First Header Logo Second Header Logo

Connection

Steven Feldman to Antibodies, Monoclonal

This is a "connection" page, showing publications Steven Feldman has written about Antibodies, Monoclonal.
Connection Strength

11.124
  1. Li W, Ghamrawi R, Haidari W, Feldman SR. Risankizumab for the Treatment of Moderate to Severe Plaque Psoriasis. Ann Pharmacother. 2020 04; 54(4):380-387.
    View in: PubMed
    Score: 0.595
  2. Hall SL, Haidari W, Feldman SR. Resolution of Guttate Psoriasis Plaques After One-time Administration of Guselkumab J Drugs Dermatol. 2019 Aug 01; 18(8):822-823.
    View in: PubMed
    Score: 0.584
  3. Bartos G, Cline A, Beroukhim K, Burrall BA, Feldman SR. Current biological therapies for use in HIV-positive patients with psoriasis: case report of gesulkumab used and review. Dermatol Online J. 2018 Nov 15; 24(11).
    View in: PubMed
    Score: 0.556
  4. Seger EW, Wechter T, Strowd L, Feldman SR. Relative efficacy of systemic treatments for atopic dermatitis. J Am Acad Dermatol. 2019 Feb; 80(2):411-416.e4.
    View in: PubMed
    Score: 0.552
  5. Feaster B, Cline A, Feldman SR. Secukinumab for psoriasis in a patient with hepatitis B. Dermatol Online J. 2018 Sep 15; 24(9).
    View in: PubMed
    Score: 0.550
  6. Cline A, Feldman SR. Risankizumab for psoriasis. Lancet. 2018 08 25; 392(10148):616-617.
    View in: PubMed
    Score: 0.546
  7. Feldman SR, Wu JJ, Rastogi S, Menges B, Lingohr-Smith M, Lin J. The budget impact of brodalumab for the treatment of moderate-to-severe plaque psoriasis on US commercial health plans. J Med Econ. 2018 May; 21(5):537-541.
    View in: PubMed
    Score: 0.527
  8. Seale L, Cardwell LA, Feldman SR. Adherence to biologics in patients with psoriasis. Expert Rev Clin Immunol. 2018 02; 14(2):155-161.
    View in: PubMed
    Score: 0.525
  9. Howell ST, Cardwell LA, Feldman SR. Treating Moderate-to-Severe Plaque Psoriasis With Guselkumab: A Review of Phase II and Phase III Trials. Ann Pharmacother. 2018 04; 52(4):380-387.
    View in: PubMed
    Score: 0.519
  10. Feldman SR, Green L, Kimball AB, Siu K, Zhao Y, Herrera V, Nyirady J, Alexis AF. Secukinumab improves scalp pain, itching, scaling and quality of life in patients with moderate-to-severe scalp psoriasis. J Dermatolog Treat. 2017 Dec; 28(8):716-721.
    View in: PubMed
    Score: 0.509
  11. Hohenberger M, Cardwell LA, Oussedik E, Feldman SR. Interleukin-17 inhibition: role in psoriasis and inflammatory bowel disease. J Dermatolog Treat. 2018 Feb; 29(1):13-18.
    View in: PubMed
    Score: 0.503
  12. Strowd LC, Feldman SR. Dupilumab for atopic dermatitis. Lancet. 2017 06 10; 389(10086):2265-2266.
    View in: PubMed
    Score: 0.500
  13. McGregor S, Farhangian ME, Feldman SR. Dupilumab for the treatment of atopic dermatitis: A clinical trial review. Expert Opin Biol Ther. 2015; 15(11):1657-60.
    View in: PubMed
    Score: 0.445
  14. Feldman SR. Department of Dermatology was blessed with a wonderful psoriasis specialist. Foreword. BioDrugs. 2013 Jan; 27 Suppl 1:1-2.
    View in: PubMed
    Score: 0.370
  15. Mudigonda P, Mudigonda T, Feneran AN, Alamdari HS, Sandoval L, Feldman SR. Interleukin-23 and interleukin-17: importance in pathogenesis and therapy of psoriasis. Dermatol Online J. 2012 Oct 15; 18(10):1.
    View in: PubMed
    Score: 0.365
  16. Smith SF, Feldman SR. Tattoo sites and psoriasis. J Drugs Dermatol. 2011 Oct; 10(10):1199-200.
    View in: PubMed
    Score: 0.340
  17. Uhlenhake EE, Feldman SR. Efficacy and safety of ustekinumab and etanercept for the treatment of psoriasis. Expert Opin Biol Ther. 2010 Jul; 10(7):1105-12.
    View in: PubMed
    Score: 0.311
  18. Feldman S. Drug Safety. J Dermatolog Treat. 2009; 20(2):71.
    View in: PubMed
    Score: 0.281
  19. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008 Jan; 58(1):125-35.
    View in: PubMed
    Score: 0.259
  20. Feldman SR. Misunderstandings. J Dermatolog Treat. 2007; 18(1):4.
    View in: PubMed
    Score: 0.244
  21. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Infliximab for inpatient psoriasis management--is there a role? J Dermatolog Treat. 2005; 16(5-6):314-8.
    View in: PubMed
    Score: 0.213
  22. Ghamrawi R, Bell KA, Balogh EA, Strowd LC, Feldman SR. Current and emerging biologics for the treatment of pediatric atopic dermatitis. Expert Opin Biol Ther. 2020 12; 20(12):1435-1445.
    View in: PubMed
    Score: 0.160
  23. Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul; 24(7):617-622.
    View in: PubMed
    Score: 0.136
  24. Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018 Dec; 29(8):769-774.
    View in: PubMed
    Score: 0.134
  25. Armstrong AW, Feldman SR, Korman NJ, Meng X, Guana A, Nyirady J, Herrera V, Zhao Y. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017 May; 28(3):200-205.
    View in: PubMed
    Score: 0.119
  26. Feldman SR, Bushnell DM, Klekotka PA, Scanlon M, Martin ML, Wade SW, Yang W, Pinto L, Kircik L, Viswanathan HN. Differences in psoriasis signs and symptom severity between patients with clear and almost clear skin in clinical practice. J Dermatolog Treat. 2016; 27(3):224-7.
    View in: PubMed
    Score: 0.112
  27. Langley RG, Feldman SR, Nyirady J, van de Kerkhof P, Papavassilis C. The 5-point Investigator's Global Assessment (IGA) Scale: A modified tool for evaluating plaque psoriasis severity in clinical trials. J Dermatolog Treat. 2015 Feb; 26(1):23-31.
    View in: PubMed
    Score: 0.099
  28. Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013 Aug; 14(4):315-26.
    View in: PubMed
    Score: 0.096
  29. Tan X, Balkrishnan R, Feldman SR. Infections associated with the use of tumor necrosis factor-a inhibitors in psoriasis. J Drugs Dermatol. 2013 Mar; 12(3):e41-5.
    View in: PubMed
    Score: 0.094
  30. Kaminska E, Patel I, Dabade TS, Chang J, Qureshi AA, O'Neill JL, Balkrishnan R, Feldman SR. Comparing the lifetime risks of TNF-alpha inhibitor use to common benchmarks of risk. J Dermatolog Treat. 2013 Apr; 24(2):101-6.
    View in: PubMed
    Score: 0.084
  31. Martin S, Feldman SR, Augustin M, Szapary P, Schenkel B. Cost per responder analysis of ustekinumab and etanercept for moderate to severe plaque psoriasis. J Dermatolog Treat. 2011 Jun; 22(3):138-43.
    View in: PubMed
    Score: 0.081
  32. Langley RG, Feldman SR, Han C, Schenkel B, Szapary P, Hsu MC, Ortonne JP, Gordon KB, Kimball AB. Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial. J Am Acad Dermatol. 2010 Sep; 63(3):457-65.
    View in: PubMed
    Score: 0.077
  33. Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011 Apr; 22(2):65-74.
    View in: PubMed
    Score: 0.077
  34. Iaconi A, Feldman SR, Balkrishnan R. Psoriasis and its treatment with adalimumab. Expert Opin Biol Ther. 2010 Jan; 10(1):133-52.
    View in: PubMed
    Score: 0.075
  35. Bansback N, Sizto S, Sun H, Feldman S, Willian MK, Anis A. Efficacy of systemic treatments for moderate to severe plaque psoriasis: systematic review and meta-analysis. Dermatology. 2009; 219(3):209-18.
    View in: PubMed
    Score: 0.073
  36. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK. Adalimumab improves health-related quality of life in patients with moderate to severe plaque psoriasis compared with the United States general population norms: results from a randomized, controlled Phase III study. Health Qual Life Outcomes. 2008 Oct 02; 6:75.
    View in: PubMed
    Score: 0.069
  37. Hick J, Feldman SR. Eligibility creep: a cause for placebo group improvement in controlled trials of psoriasis treatments. J Am Acad Dermatol. 2007 Dec; 57(6):972-6.
    View in: PubMed
    Score: 0.064
  38. Menter A, Feldman SR, Weinstein GD, Papp K, Evans R, Guzzo C, Li S, Dooley LT, Arnold C, Gottlieb AB. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol. 2007 Jan; 56(1):31.e1-15.
    View in: PubMed
    Score: 0.060
  39. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: which biologic is best? J Dermatolog Treat. 2006; 17(2):96-107.
    View in: PubMed
    Score: 0.057
  40. Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB. Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial. J Am Acad Dermatol. 2005 Mar; 52(3 Pt 1):425-33.
    View in: PubMed
    Score: 0.054
  41. Rapp SR, Feldman SR. The promise and challenge of new biological treatments for psoriasis: how do they impact quality of life? Dermatol Ther. 2004; 17(5):376-82.
    View in: PubMed
    Score: 0.050
  42. Shaw MK, Davis SA, Feldman SR, Fleischer AB. Trends in systemic psoriasis treatment therapies from 1993 through 2010. J Drugs Dermatol. 2014 Aug; 13(8):917-20.
    View in: PubMed
    Score: 0.026
  43. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB, Lebwohl M, Koo JY, Elmets CA, Korman NJ, Beutner KR, Bhushan R. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008 May; 58(5):826-50.
    View in: PubMed
    Score: 0.017
  44. Gottlieb A, Korman NJ, Gordon KB, Feldman SR, Lebwohl M, Koo JY, Van Voorhees AS, Elmets CA, Leonardi CL, Beutner KR, Bhushan R, Menter A. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol. 2008 May; 58(5):851-64.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.